Halozyme Therapeutics Inc. (NASDAQ: HALO) is 7.39% higher on its value in year-to-date trading and has touched a low of $29.85 and a high of $48.74 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $39.84 in the last trading session, with the day’s loss setting it -0.15%.
Currently trading at $39.69, the stock is 9.97% and 10.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.91 million and changing -0.38% at the moment leaves the stock 5.42% off its SMA200. HALO registered -18.25% loss for a year compared to 6-month loss of -6.48%. The firm has a 50-day simple moving average (SMA 50) of $7.47 and a 200-day simple moving average (SMA200) of $13.71.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 15.34% gain in the last 1 month and extending the period to 3 months gives it a -2.86%, and is 3.47% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.53% over the week and 3.33% over the month.
Halozyme Therapeutics Inc. (HALO) has around 373 employees, a market worth around $5.03B and $829.25M in sales. Current P/E ratio is 18.82 and Fwd P/E is 8.96. Profit margin for the company is 33.96%. Distance from 52-week low is 32.96% and -18.57% from its 52-week high. The company has generated returns on investments over the last 12 months (17.79%).
Halozyme Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at $0.77 with sales reaching $213.56M over the same period.The EPS is expected to grow by 25.54% this year, but quarterly earnings will post 15.10% year-over-year. Quarterly sales are estimated to grow 21.70% in year-over-year returns.
573 institutions hold shares in Halozyme Therapeutics Inc. (HALO), with institutional investors hold 101.51% of the company’s shares. The shares outstanding are 126.77M, and float is at 125.49M with Short Float at 6.09%. Institutions hold 100.39% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 18.6 million shares valued at $671.06 million. The investor’s holdings represent 14.10% of the HALO Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 13.14 million shares valued at $473.83 million to account for 9.96% of the shares outstanding. The other top investors are Artisan Partners Limited Partnership which holds 7.46 million shares representing 5.65% and valued at over $269.06 million, while State Street Corporation holds 4.93% of the shares totaling 6.5 million with a market value of $234.61 million.
Halozyme Therapeutics Inc. (HALO) Insider Activity
A total of 16 insider transactions have happened at Halozyme Therapeutics Inc. (HALO) in the last six months, with sales accounting for 8 and purchases happening 8 times. The most recent transaction is an insider sale by LaBarre Michael J., the company’s SVP, CHIEF TECHNICAL OFFICER. SEC filings show that LaBarre Michael J. sold 10,000 shares of the company’s common stock on Feb 28 at a price of $39.55 per share for a total of $0.4 million. Following the sale, the insider now owns 0.16 million shares.
Halozyme Therapeutics Inc. disclosed in a document filed with the SEC on Feb 27 that LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Feb 27 and was made at $39.95 per share for $0.4 million. Following the transaction, the insider now directly holds 0.16 million shares of the HALO stock.
Still, SEC filings show that on Jan 17, LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) disposed off 10,000 shares at an average price of $36.00 for $0.36 million. The insider now directly holds 151,911 shares of Halozyme Therapeutics Inc. (HALO).
Halozyme Therapeutics Inc. (HALO): Who are the competitors?
One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 141.16% up over the past 12 months.Johnson & Johnson (JNJ) lies in the list of competitors of the Halozyme Therapeutics Inc. and is 5.89% higher over the same period from HALOSanofi ADR (SNY) is 2.08% up on the 1-year trading charts.
